Save to Existing Project
Save to a New Project
An immunotherapy based on co-selection using a pair of complementary antibodies (i.e. anti-foreign and anti-anti-self antibodies) inducing tolerance to an inflammatory response....
Our North America-based client is developing and owns intellectual property rights to a novel immunotherapeutic product. This antibody-based immuno-therapeutic product has been demonstrated to significantly down-regulate inflammation in an inflammatory bowel disease (ulcerative colitis and Crohn’s) mouse model. The therapeutic product is composed of a combination of antibodies. The antibody combination is administered intravenously and intraperitoneal.
The immunotherapy is based on the symmetrical immune network theory wherein co-selection plays a central role in the regulation of the system. They use a combination of anti-anti-self antibodies and anti-foreign antibodies and have shown a marked prolongation of skin graft survival in mice, and the stabilization of an immune response in the mouse model of inflammatory bowel disease (ulcerative colitis).
A detailed manuscript with technical details and experimental results as available on request.
Type of Business Relationship Sought
Our client aspires to partner at the pre-clinical stage, with a medium to large Pharmaceutical company, for the development of its anti-inflammatory/cancer product. The company seeks a partner that is able to provide an upfront licensing fee in exchange for the first right to negotiate a global licensing agreement. The company is seeking, in order of priority: 1. A CRaDA (Collaborative Research and Development Agreement) / Licensing agreement Nature of Partnership: The partner would share / cover the cost of development providing upfront and milestone payments (full details to be discussed) 2. Divestment of $5M for development of technologies to IND
Last Updated Jan 2017